American Lung Association Pushes Annual Respiratory Virus Vaccines Amid Rising Hospitalization Risks
Event summary
- American Lung Association launches fall campaign urging annual respiratory virus vaccinations for flu, COVID-19, and RSV.
- 2025-2026 flu season caused 32M illnesses, 390K hospitalizations, and 24K deaths per CDC data.
- COVID-19 and RSV contributed to 240K and 340K hospitalizations respectively in 2025-2026.
- Campaign targets 35M Americans with lung disease, highlighting vaccine importance for high-risk groups.
- Moderna supports the educational initiative focused on vaccine safety and accessibility.
The big picture
The American Lung Association's campaign underscores the ongoing challenge of respiratory virus prevention, particularly as seasonal spikes strain healthcare resources. With rising hospitalization rates from flu, COVID-19, and RSV, the push for annual vaccinations aligns with broader public health efforts to mitigate severe outcomes. The initiative also highlights the vulnerability of individuals with chronic lung conditions, emphasizing the need for targeted health interventions.
What we're watching
- Vaccine Uptake
- Whether the campaign can significantly increase vaccination rates among high-risk populations, particularly those with lung disease.
- Seasonal Trends
- The pace at which respiratory virus cases rise during the 2026-2027 season and its impact on healthcare systems.
- Public Health Impact
- How effective the Lung Association's educational efforts are in reducing severe illness and hospitalizations.
Related topics